1.Effects of peroxisome proliferators activated receptor-ganmma(PPAR-γ)on ischemia-reperfusion injury of bilr ducts after orthotopic liver transplantationwith
Honghong PEI ; Yiming LI ; Zhengliang ZHANG ; Minlong LIU ; Ling BAI ; Fei MIAO
Chinese Journal of Emergency Medicine 2009;18(3):277-280
Objective To explore the effects and mechanism of peroxisome proliferators activated receptor-gamma(PPAR-γ)and its ligand rosiglitazone on ischemia-reperfusion injury of the donor bile ducts.Method Forty-two SD rats were randomly divided into three groups with fourteen rats in each:the sham operation group (SO),ischemia-reperfusion(I/R)group and I/R+rosiglitazone group(I/R+Ros).The animal model of is-chemia-reperfusion occurred in the orthotopically transplanted liver was used.Tne signal pathway of iuflanunatory response of bile duets of the transplanted hver and the variations of associated cytokines were detected by the signal transduction pathway-finder gene array and cytokine antibody chips.The pathological changes and the biochemical markers of the donor liver were assessed by histopathological score and the estimation of the functional changes of some other organs.Data were analyzed by using SPSS version 10.0 software package.Statistical analysis was car-ried out by using one-way anova and Bonferroni test.Results Compared with the SO group and I/R+Ros group.the expression of NF-кB gene of I/R group to more than two times,and the levels of IL-1α,IL-1β and TNF-α pro-tein expressions in I/R group went up over double too.Compared with I/R group,the histopathological score and the biochemical markers of I/R+Ros group were significantly lower (P<0.05,P<0.01,respectively).Con-clusions PPAR-γ and its ligand rosiglitazone have protective effects on ischemia-reperfusion injury to donor bile ducts.The mechanism may be attributed to decrease in the release of inflammatory mediators(IL-1α,IL-1β,TNF-α and so on)resulted from the down-expression of decreased due to NF-кB.
2.Clinical efficacy of Qingyi decoction combined with DAR for the treatment of acute pancreatitis
Zhengliang ZHANG ; Zhenghai BAI ; Lifeng DU ; Shiyuan SUN ; Minlong LIU ; Fei MIAO ; Honghong PEI
Chinese Journal of Emergency Medicine 2013;22(7):760-764
Objective To explore the clinical efficacy of Qingyi decoction (a preparation of Chinese herbal medicine) combined with DAR (combined use of dexamethasone,anisodamine and rhubarb) for the treatment of acute pancreatitis.Methods A total of 387 eligible patients met the criteria of acute pancreatitis were enrolled from January 2005 to April 2012 for prospective study.All patients,mild acute pancreatitis (MAP) or severe acute pancreatitis (SAP),were divided (random niumber) into four groups,namely conventional therapy (T),DAR therapy (DAR),Qingyi decoction therapy (Q) and Qingyi decoction combined with DAR therapy (Q + DAR).Outcome,fasting time,serum amylase,abdominal pain relief time,pancreatic or peri-pancreatic complications and average hospital-stay were analvzed with SPSS 13.0 statistic software.P < 0.05 was considered statistically significant.Results None of MAP patients died.Of SAP patients,there was no difference in mortality among different groups (P > 0.05).length of fasting time,tine elapsed for abdominal pain relief,time required for normalized serum amylase level and length of hospital stay in MAP patients were significantly shorter than those in SAP patients regardless of different therapies (P < 0.05).Either patients of SAP or MAP treated with Q + DAR or DAR suffered shorter length of time than those treated with T or Q in respect of fasting,abdominal paiu relief,serum amylase level normalization and hospital stay (P < 0.05).For SAP or MAP patients,there was no difference in abdominal pain relief time between receiving DAR and Q + DAR treatment (P > 0.05),but the fasting time in Q + DAR was shorter than that in DAR (P < 0.05).Patients with SAP were more likely to suffer pancreatic or per-pancreatic complications than those with MAP,but there was no difference for SAP or MAP with different treatments.Conclusions DAR or Q + DAR was an alternative to conventional treatment for MAP or SAP,and they were both superior to conventional treatment.And Q + DAR was more advantageous than DAR when fasting time,hospital-stay time and cost were considered.
3.HIS failure response capacity of medical staffs in three tertiary hospitals in Xi'an and its influence factors
Xue YAN ; Minlong ZHANG ; Rui CUI ; Xiwen LIU
Chinese Journal of Modern Nursing 2017;23(4):518-521
ObjectiveTo explore the hospital information system (HIS) failure response capacity of medical staffs in Xi'an and provide evidences for hospitals to carry out individual education and guidance. MethodsSelf-designed general information and HIS failure response capacity questionnaires were used to investigate 210 medical staffs from three tertiary hospitals in Xi'an.Results Knowledge level of HIS failure response in medical staffs was general and their pass rate of the test was 62.9%. Univariate analysis showed that there was significant difference in the pass rate of staffs with different education level,HIS failure experiences and HIS failure related education experience (χ2=7.027,8.842,5.484;P<0.05). Binary logistic regression analysis showed that education level,working experience,hospital information system failure experience and HIS failure related education experience were main influencing factors of HIS failure response capacity of medical staffs.Conclusions The current HIS failure education system is not perfect in our country and the hospital information system failure response knowledge and capacity of medical stuffs should be improved. Hospitals could carry out various forms of education and training to improve the HIS failure response capacity of medical staffs.
4.Successful management of massive gastrointestinal bleeding using recombinant factor VIIa in an elderly patient with respiratory and renal failure.
Minlong LIU ; Guoen WANG ; Qi MA ; Junming REN ; Lei GUO ; Jun ZHANG
Journal of Southern Medical University 2014;34(8):1215-1216
Recombinant activated factor VII (rFVIIa) is a novel therapeutic agent for life-threatening massive gastrointestinal bleeding. We report a case of massive gastrointestinal bleeding in a 78-year-old female patient with respiratory and renal failure. After failure of management of the bleeding with routine pharmacotherapy, we gave the patient rFVIIa injection at the dose of 20 µg/kg and the bleeding was rapidly controlled. Adverse side effects of the drug were not observed in this patient.
Aged
;
Factor VIIa
;
therapeutic use
;
Female
;
Gastrointestinal Hemorrhage
;
drug therapy
;
Humans
;
Recombinant Proteins
;
therapeutic use
;
Renal Insufficiency
;
Respiratory Insufficiency